The first-to-market hybrid closed loop CGM and "smart" insulin pens are 2 of our picks for 2017’s best tech advances in diabetes management.
From the first-to-market hybrid closed loop technology for continuous glucose monitoring to the first cloud-connected injectable therapy delivery device available for home use, the slides above highlight 5 new technologies that won the Patient Care editor's choice for the best tech advances in 2017 for management of type 1 and type 2 diabetes.Â
Dexcom G6 CGM ** QuiO Smartinjector Platform ** Freestyle Libre Pro CGM ** Smart insulin pens ** Medtronic MiniMed 6706 Insulin Pump System
Dexcom is targeting G6 for a third quarter 2017 FDA submission and 2018 launch, with a second generation expected in 2020. MORE INFORMATION.
The QuiO platform consists of an Internet of Things-enabled device and HIPAA-compliant companion software. MORE INFORMATION
The hybrid glucose monitoring system for clinicians was FDA approved in 2016; provides “Ambulatory Glucose Profile.” MORE INFORMATION
Smart insulin pens from a varitey of companies calculate/track insulin doses, relay data to smartphone app; record time of dosing. MORE INFORMATION (example, inPen)
First CGM sensor FDA-approved to control insulin dosing; allows programming to automatically adjust insulin delivery. MORE INFORMATION.